Changes in Clinical, Pulmonary Function, Quality of Life and Costs in a Cohort of Asthmatic Patients Followed for 10 Years;Cambios en la clínica, la función pulmonar, la calidad de vida y los costes en una cohorte de pacientes asmáticos seguidos durante 10 años

Archivos de Bronconeumologia

Volumn 47, Issue 10, 2011, Pages 482-487

  Serra Batlles, J ^a   Plaza, V ^b   Comella, A ^c  

^a HOSPITAL GENERAL DE VIC   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

Author keywords

Asthma; Asthma evolution; Lung function; Pharmacoeconomics; Quality of life

Indexed keywords

ARTICLE; ASTHMA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; EMERGENCY WARD; FOLLOW UP; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; QUALITY OF LIFE; RISK REDUCTION; ADULT; CAUSE OF DEATH; COHORT ANALYSIS; DESCRIPTIVE RESEARCH; DISEASE COURSE; FEMALE; FINANCIAL MANAGEMENT; FORCED EXPIRATORY VOLUME; HEALTH SERVICE; LONGITUDINAL STUDY; MEDICAL INFORMATION; MORBIDITY; MORTALITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOMATOLOGY;

EID: 80053383866     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.05.011     Document Type: Article

References (31)

1. European Community Respiratory Health Survey II Steering Committee. The European Community Respiratory Health Survey II.. Eur Respir J. 2002; 20:1071-9.
2. Sobradillo V., Miravitlles M., Jimenez C.A., Gabriel R., Viejo J.L., Masa J.F., et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 1999, 35:159-166.
3. Worldwide variation in prevalence of symptoms of asthma, allergic rhino conjunctivitis, and atopic eczema: ISAAC. Lancet 1998, 351:1225-1232. The International Study of Asthma an Allergies in Childhood (ISAAC).
4. Weiss K.B., Gergen P.J., Hodgson T.A. An economic evaluation of asthma in the United States. N Engl J Med 1992, 326:862-866.
5. Haahtela T., Tuomisto L.E., Pietinalho A., Klaukka T., Erhola M., Kaila M., et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006, 61:663-670.
6. Sánchez-Bahíllo M., García-Marcos L., Pérez-Fernández V., Martínez-Torres A.E., Sánchez-Solís M. Evolución de la mortalidad por asma en España, 1960-2005. Arch Bronconeumol 2009, 45:123-128.
7. Global Initiative for Asthma (GINA). Global strategy for asthma management and Prevention. NHLBI/WHO workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. January 1995, NIH, publication number 95±3659.
8. Plaza V., Álvarez F.J., Casan P., Cobos N., López Viña A., Llauger M.A., et al. Guía Española para el Manejo del Asma (GEMA). Arch Bronconeumol 2003, 39(Supl 5):1-42. en calidad de Comité Ejecutivo de la GEMA y en representación del grupo de redactores.
9. Suissa S., Ernst P., Benayoun S., Baltzan M., Cai B. Low-dose inhaled corticosteroids and prevention of death from asthma. N Engl J Med 2000, 343:332-336.
10. 2-adrenérgicos de acción larga y glucocorticoides inhalados en la morbimortalidad de 1.543 episodios de exacerbación grave de asma. Arch Bronconeumol 2009, 45:545-549.
11. Serra-Batlles J., Plaza V., Morejón E., Comella A., Brugués J. Cost of asthma according to the degree of severity. Eur Resp J 1998, 12:1322-1326.
12. Vicente Plaza, Joan Serra-Batlles, Elena Morejón, Montserrat Ferrer Quality of life and economics features of elderly asthmatics. Respiration 2000, 67:65-70.
13. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors November 1986. Am Rev Respir Dis 1987, 136:225-244. Standards for the diagnosis, care of patients with chronic obstructive pulmonary disease (COPD), asthma.
14. International Consensus Report on Diagnosis and Treatment of Asthma. Clin Exp Allergy 1992;1:1-72.
15. Sanchis J., Casan P., Castillo J., González N., Palenciano L., Roca J. Normativa para la práctica de la espirometría forzada. Arch Bronconeumol 1989, 25:132-142.
16. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
17. Ferrer M., Alonso J., Prieto L., Plaza V., Monsó E., Marrades R., et al. Validity and reliability of the St. George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J 1996, 9:1160-1166.
18. Instituto Nacional de Estadística (INE). Boletín mensual de estadística, Madrid, 1995; 37(enero): 147.
19. Instituto Nacional de Estadística (INE) [16 Jun 2005]. Disponible en: INEbase-www.ine.es.
20. De Marco R., Marcon A., Jarvis D., Accordini S., Almar E., Bugiani M., et al. Pronostic factors of asthma severity: A 9-year international prospective cohort study. J Allergy Clin Immunol 2006, 117:1249-1256.
21. Prieto L., BadiolaC, Villa J.R., Plaza V., Molina J., Cimas E. On behalf of the ASMAP1 investigator group. Asthma control: do patients' and physicians' opinions fit with patients' asthma control status?. J Asthma 2007, 44:461-467.
22. Demoly P., Paggiaro P.L., Plaza V., Bolge S.C., Kannan H., Sohier B., et al. Prevalence of asthma control among adults in France, Germany, Italy Spain and U.K. Eur Respir Rev 2009, 18:105-112.
23. Chapman K.R., Boulet L.P., Rea R.M., Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008, 31:320-325.
24. Plaza V., Bolívar I., Giner J., Llauger Ma A., López-Viña A., Quintano J.A., et al. Opinión, conocimientos y grado de seguimiento referidos por los profesionales sanitarios españoles de la Guía Española para el Manejo del Asma (GEMA) Proyecto GEMA-Test. Arch Bronconeumol 2008, 44:245-251.
25. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26. SMART Study Group.
26. Salpeter S.R., Buckley N.S., Ormiston T.M., Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006, 144:904-912.
27. Sears M.R., Ottosson A., Radner F., Suissa S. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009, 33:21-32.
28. Lange P., Parner J., Vestbo J., Schnohr P., Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998, 339:1194-1200.
29. Vonk J.M., Jongepier H., Panhuysen C.I., Schouten J.P., Bleecker E.R., Postma D.S. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003, 58:322-327.
30. Bai T.R., Vonk J.M., Postma D.S., Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007, 30:452-456.
31. Martínez-Moragón E., Serra-Batlles J., De Diego A., Palop M., Casan P., Rubio-Térres C., et al. Coste económico del paciente asmático en España (estudio AsmaCost). Arch Bronconeumol 2009, 45:481-486. y Grupo de investigadores del Estudio AsmaCost.